Moxlocin0.5%

Moxlocin is a fourth-generation fluoroquinolone antibacterial indicated for infections caused by susceptible strains of bacteria. Because of the risk of serious, potentially irreversible adverse effects associated with fluoroquinolones, Moxlocin should be reserved for patients who have no alternative treatment options for certain indications (acute bacterial sinusitis and acute bacterial exacerbation of chronic bronchitis).

Established/FDA-approved uses (systemic, oral/intravenous)

• Community-acquired pneumonia, including cases caused by multi-drug-resistant strains of Streptococcus pneumoniae
• Acute bacterial sinusitis (reserve for patients with no other treatment options)
• Acute bacterial exacerbation of chronic bronchitis (reserve for patients with no other treatment options)
• Uncomplicated skin and skin structure infections
• Complicated skin and skin structure infections
• Complicated intra-abdominal infections (including polymicrobial infections such as abscess), used in combination with an appropriate anti-anaerobic agent when needed
• Plague (including pneumonic and septicemic plague), and post-exposure prophylaxis of plague, based on efficacy studies in animals combined with limited human data, as human efficacy studies are not feasible

Ophthalmic formulation

The ophthalmic solution of Moxlocin is indicated for bacterial conjunctivitis caused by susceptible organisms.

Important limitation

Moxlocin achieves relatively low concentrations in urine and is not recommended for the treatment of urinary tract infections. Moxlocin is not effective against viral infections such as the common cold or influenza and should be used only for infections proven or strongly suspected to be caused by susceptible bacteria.

Each formulation of Moxifloxacin Hydrochloride contains Moxifloxacin Hydrochloride as the active pharmaceutical ingredient. In Bangladesh, Moxifloxacin Hydrochloride is available as oral film-coated tablets (commonly 400 mg), intravenous infusion solution (400 mg/250 mL), and an ophthalmic solution for eye infections. Excipients vary by manufacturer and formulation.

Moxlocin is a synthetic, broad-spectrum, fourth-generation fluoroquinolone antibacterial agent. Compared with earlier fluoroquinolones, it has enhanced activity against Gram-positive organisms (including Streptococcus pneumoniae) and clinically useful activity against certain anaerobic bacteria and atypical pathogens (e.g., Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila), in addition to activity against many Gram-negative organisms.

Moxlocin is administered orally or by intravenous infusion for systemic infections, and as a topical ophthalmic solution for bacterial conjunctivitis. Oral Moxlocin is well absorbed with high bioavailability, allowing switch from intravenous to oral therapy in appropriate patients.

Moxlocin belongs to the fluoroquinolone class of antibacterial agents (fourth-generation).

Mechanism of action

Moxifloxacin Hydrochloride exerts a bactericidal effect by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes required for bacterial DNA replication, transcription, repair, and recombination. Dual inhibition of these two enzyme targets contributes to its broad spectrum of activity and reduces the likelihood of resistance developing via a single-step mutation.

Pharmacokinetics

• Absorption: Rapidly and almost completely absorbed after oral administration; absolute bioavailability is approximately 90%, largely unaffected by food.
• Distribution: Widely distributed into body tissues and fluids, including lung tissue and sinus mucosa; plasma protein binding is approximately 30-50%.
• Metabolism: Undergoes hepatic metabolism (glucuronide and sulfate conjugation) without significant involvement of the cytochrome P450 system.
• Excretion: Eliminated via a combination of renal excretion and biliary/fecal excretion of unchanged drug and metabolites; elimination half-life is approximately 12 hours, supporting once-daily dosing.

Moxlocin tablets should be swallowed whole with a full glass of water, with or without food. Doses should be separated by at least 4 hours (before) or 8 hours (after) from antacids, iron, zinc, or multivitamin products containing these minerals. The injectable form is given only by slow intravenous infusion (over about 60 minutes) by a healthcare professional. The ophthalmic solution should be instilled into the affected eye(s) only, avoiding contact of the dropper tip with the eye or surrounding skin.

Moxlocin has several clinically significant drug interactions:

• Antacids, sucralfate, and multivitamins/minerals (iron, zinc): These form chelation complexes with Moxlocin, substantially reducing its absorption and effectiveness. Administer Moxlocin at least 4 hours before or 8 hours after these products.
• Class IA antiarrhythmics (e.g., quinidine, procainamide) and Class III antiarrhythmics (e.g., amiodarone, sotalol): Concurrent use is contraindicated because of additive QT-interval prolongation and increased risk of serious arrhythmia (see Contraindications).
• Other QT-prolonging drugs (e.g., certain antipsychotics, some antidepressants, some antiemetics): Concurrent use should be avoided due to additive risk of QT prolongation.
• Warfarin and other oral anticoagulants: Moxlocin may enhance anticoagulant effects; monitor prothrombin time/INR closely and watch for bleeding.
• Antidiabetic agents (insulin, oral hypoglycemics): Concurrent use may cause significant blood glucose disturbances (both hypoglycemia and hyperglycemia); monitor blood glucose closely, particularly in diabetic patients.
• Corticosteroids: Concurrent use increases the risk of tendinitis and tendon rupture, especially in older adults.
• Nonsteroidal anti-inflammatory drugs (NSAIDs): Concurrent use with fluoroquinolones such as Moxlocin may increase the risk of central nervous system stimulation and seizures.

Most patients tolerate Moxlocin well, but side effects can occur.

Common side effects

• Nausea, diarrhea, vomiting, abdominal pain, dyspepsia
• Headache, dizziness
• Taste disturbance, insomnia

Less common but serious side effects

• Tendinitis and tendon rupture (especially Achilles tendon), which can occur during or after treatment (see Precautions and Warnings)
• Peripheral neuropathy (numbness, tingling, weakness) that may be irreversible
• Central nervous system effects: seizures, confusion, tremors, hallucinations, anxiety, depression, and rarely suicidal thoughts
• QT interval prolongation and, rarely, serious arrhythmias including torsades de pointes
• Fulminant hepatitis potentially leading to liver failure (rare, but reported specifically with this drug); also milder transaminase elevations and jaundice
• Photosensitivity (increased sensitivity to sunlight, causing exaggerated sunburn)
• Clostridioides difficile-associated diarrhea, ranging from mild to life-threatening colitis
• Hypersensitivity reactions, including rash, and rarely severe skin reactions (e.g., Stevens-Johnson syndrome) or anaphylaxis
• Aortic aneurysm and aortic dissection (rare but serious risk signal, especially in older adults with risk factors)
• Blood glucose disturbances (hypoglycemia or hyperglycemia), particularly in diabetic patients

Patients should seek prompt medical attention if they experience tendon pain/swelling, unusual numbness or tingling, palpitations or fainting, yellowing of the skin/eyes, severe diarrhea, sudden severe chest/back/abdominal pain, or signs of an allergic reaction while taking Moxlocin.

Pregnancy: Moxlocin is generally avoided during pregnancy. Animal studies have shown fluoroquinolones, including Moxlocin, can cause cartilage and joint damage in immature animals, raising theoretical concern for the developing fetus, and some animal studies have shown embryo-fetal effects at maternally toxic doses. Moxlocin should be used during pregnancy only if the potential benefit to the mother clearly justifies the potential risk to the fetus and no safer alternative antibiotic is suitable; consult a physician before use.

Lactation: It is not known whether Moxlocin is excreted in human breast milk, though related fluoroquinolones are excreted into breast milk in small amounts. Because of the potential risk of joint/cartilage effects and other adverse effects in the nursing infant, a decision should be made whether to discontinue breastfeeding or discontinue Moxlocin, taking into account the importance of the drug to the mother; consult a physician.

Take Moxlocin exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice.

• Tendinitis and tendon rupture: Fluoroquinolones, including Moxlocin, are associated with an increased risk of tendinitis and tendon rupture, most commonly involving the Achilles tendon, across all ages. Risk is higher in patients over 60 years, those taking corticosteroids concurrently, and organ transplant recipients. Stop Moxlocin and seek medical attention immediately if pain, swelling, or inflammation of a tendon occurs.
• Peripheral neuropathy: Moxlocin may cause peripheral neuropathy that can occur soon after starting treatment and may be irreversible. Discontinue immediately if symptoms of neuropathy (pain, burning, tingling, numbness, weakness) occur.
• Central nervous system effects: May cause seizures, increased intracranial pressure, confusion, and rarely psychiatric reactions including suicidal thoughts. Use with caution in patients with known or suspected CNS disorders (e.g., epilepsy).
• Myasthenia gravis: Avoid use in patients with known myasthenia gravis, as fluoroquinolones can worsen muscle weakness and precipitate life-threatening respiratory failure.
• QT prolongation: Moxlocin carries a relatively higher risk of QT-interval prolongation than some other fluoroquinolones. Use with caution in patients with risk factors for arrhythmia (e.g., significant bradycardia, recent myocardial ischemia, uncorrected electrolyte disturbances) even outside the contraindicated combinations listed above (see Contraindications).
• Aortic aneurysm/dissection: Fluoroquinolones are associated with an increased risk of aortic aneurysm and dissection, particularly in older adults; avoid use in patients with a history of aneurysm or at increased risk unless no other treatment options are available.
• Hepatotoxicity: Rare but serious cases of fulminant hepatitis potentially progressing to liver failure (including fatal cases) have been reported. Discontinue Moxlocin immediately if signs or symptoms of hepatitis (e.g., jaundice, dark urine, persistent nausea, right upper abdominal pain) occur.
• C. difficile-associated diarrhea: May occur during or up to several months after treatment; evaluate if diarrhea occurs and manage appropriately.
• Photosensitivity: Avoid excessive sun/UV exposure and use sun protection during treatment.
• Not for urinary tract infections: Moxlocin achieves low urinary concentrations and should not be relied upon to treat urinary tract infections.
• Use only for confirmed or strongly suspected bacterial infections to help prevent the development of drug-resistant bacteria.

In case of a suspected Moxlocin overdose, seek immediate medical attention or contact a poison control center/emergency services right away. There is no specific antidote. Management is supportive and symptomatic, and may include gastric decontamination if performed promptly by medical professionals, close monitoring of ECG (for QT prolongation) and vital signs, maintenance of adequate hydration, and general supportive care. Hemodialysis and peritoneal dialysis do not effectively remove Moxlocin from the body. Do not attempt to manage an overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment

No dosage adjustment of Moxlocin is necessary in patients with any degree of renal impairment, including those on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD), as renal excretion is not the primary route of elimination.

Hepatic impairment

Caution is advised in patients with hepatic impairment, since rare but serious cases of fulminant hepatitis and liver failure have been reported with Moxlocin. Moxlocin has not been adequately studied in patients with severe (Child-Pugh Class C) hepatic impairment or cirrhosis with ascites, and use in such patients should be avoided unless the anticipated benefit outweighs the risk.

Elderly patients

Elderly patients, particularly those on concurrent corticosteroids or with cardiac risk factors, are at increased risk of tendon disorders, QT prolongation, and aortic aneurysm/dissection with Moxlocin; use with appropriate caution and monitoring.

Pediatric use

See Pediatric Uses section below.

Duration of Moxlocin therapy depends on the indication and typically ranges from 5 days (acute bacterial exacerbation of chronic bronchitis) to as long as 21 days (complicated skin/skin structure infections), as outlined in the Dosage and Administration section. Patients must complete the full course prescribed by their physician even if symptoms resolve earlier, to ensure eradication of infection and reduce the risk of antibiotic resistance.

Moxifloxacin Hydrochloride is classified as a fourth-generation fluoroquinolone antibacterial (a subclass of quinolone antibiotics).

Moxifloxacin Hydrochloride inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, and repair, resulting in bactericidal activity against a broad range of susceptible organisms, including some Gram-positive, Gram-negative, atypical, and anaerobic bacteria.

C

Moxlocin is not recommended for use in children and adolescents under 18 years of age. Safety and efficacy in pediatric patients have not been established, and fluoroquinolones as a class have been associated with an increased incidence of musculoskeletal adverse events (e.g., arthralgia, tendon disorders) in pediatric patients compared with controls in clinical trials, as well as arthropathy in juvenile animal studies. For pediatric infections, alternative antibiotics with an established pediatric safety profile are generally preferred, and any use of Moxlocin in a child would be an off-label decision made by a specialist physician only when no suitable alternative exists.